Research
Hormonal
SGLT2 inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin) lower blood glucose through an insulin-independent mechanism by blocking glucose reabsorption in the kidneys, providing modest weight loss and blood pressure reduction.
SGLT2 inhibitors are oral medications that help your kidneys remove sugar from your body through urine. This lowers blood sugar without relying on insulin, making them useful even in advanced diabetes. They also help with weight and blood pressure. Watch for signs of urinary or genital infections.
GoodSupportsHIGH confidence
SGLT2 inhibitors provide insulin-independent glucose lowering by blocking glucose reabsorption in the proximal renal tubule by inhibiting SGLT2... These drugs provide modest weight loss and blood pressure reduction.
Why this rating
Clinical review describing class effects.
Source
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
Arun Chaudhury et al. · Frontiers in Endocrinology · 2017
DOI 10.3389/fendo.2017.00006
narrative_reviewCited 1,474×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modifications, including moderate weight loss (approx 7% body weight) and regular exercise (150 min/week moderate intensity), are cost-effective in preventing or delaying the onset of diabetes and improving glycemic control.Strong
- Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.Good
- GLP-1 receptor agonists (e.g., Liraglutide, Exenatide) promote weight loss and improve glycemic control by mimicking incretin hormones, delaying gastric emptying, and increasing satiety, making them advantageous for obese T2DM patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →